Search

L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal

C-101, also called Myodur, is developed for the treatment of Duchenne’s muscular dystrophy (DMD) which is a morbid genetic disease that can lead to death in late adolescence due to accelerated skeletal

DTS-201

It is activated in the tumor environment.

Cynodon dactylon pollen

It can be cutaneously, intradermally and subcutaneously administered to initiate an immune response in case of an allergic reaction.

Triacetin

AN-9

Pivaloyloxymethyl butyrate (AN-9), an acyloxyalkyl ester prodrug of butyric acid (BA), exhibited low toxicity and significant anticancer activity in vitro and in vivo. … greater potency than BA at inducing malignant cell differentiation and tumor growth inhibition and has demonstrated more favorable toxicological, pharmacological, and pharmaceutical properties than BA in

Vimseltinib

A265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results in … [L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate

Quinacrine

An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. … It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.

XL820

XL820 is investigated for use/treatment in solid tumors. XL820 is a solid. … XL820 exhibits dose-dependent growth inhibition in models of breast carcinoma, gliomas and leukemia.

Mebendazole

A benzimidazole that acts by interfering with carbohydrate metabolism and inhibiting polymerization of microtubules. [PubChem]

Dodecyldimethylamine N-oxide